Kymanox’s Post

Watch our on-demand webinar on overcoming upstream and downstream process barriers for large-scale AAV production! Watch our esteemed speakers from #EncodedTherapeutics and #ThermoFisherScientific share their valuable insights and strategies to optimize your AAV manufacturing process, ultimately accelerating the development of safe and effective gene therapies. Watch here: https://lnkd.in/gaXj4Vbf Key Takeaways: ✅ Discover an end-to-end solution for the development and commercial production of AAV. ✅ Learn about new products and technologies that can enhance production efficiency, address regulatory concerns, and facilitate the scale-up of AAV production protocols. ✅ Gain a comprehensive understanding of how gene therapy developers are currently tackling critical manufacturing challenges. Stream today to learn more about gene therapy manufacturing!

Watch our on-demand webinar on overcoming upstream and downstream process barriers for large-scale AAV production! Watch our esteemed speakers from #EncodedTherapeutics and #ThermoFisherScientific share their valuable insights and strategies to optimize your AAV manufacturing process, ultimately accelerating the development of safe and effective gene therapies. Watch here: https://lnkd.in/gaXj4Vbf Key Takeaways: ✅ Discover an end-to-end solution for the development and commercial production of AAV. ✅ Learn about new products and technologies that can enhance production efficiency, address regulatory concerns, and facilitate the scale-up of AAV production protocols. ✅ Gain a comprehensive understanding of how gene therapy developers are currently tackling critical manufacturing challenges. Stream today to learn more about gene therapy manufacturing!

We’re modernizing cell and gene therapy process development with ‘Biology + Engineering + Digital’ innovation… Scientific innovation within the cell and gene therapy industry continues to be groundbreaking. However, current development bottlenecks limit widespread patient access to life changing cell and gene therapies (CGT). We’re on a mission to change this, by rethinking manufacturing processes and leaving manual, paper-based processes in the past. We believe a digitally-native approach will power a new generation of these personalized therapies. Utilizing Benchling’s R&D Cloud, our fully automated and standardized CGT manufacturing platform allows for scalable development from pre-clinical to commercial manufacturing by enabling: 🔷 Faster, more accurate data capture and greater process consistency 🔷 Improved efficiency and reduce process development time 🔷 Increase in data quality and interoperability “We can now go to our partners and say, ‘we know this part of the process could be run more efficiently, and here is the data we’ve produced to support it with Benchling and our platform’ — we’re not just talking the talk, we’re walking the walk.” - Matt Todd, Head of Architecture, Ori Biotech Read our full case study in collaboration with Benchling → https://lnkd.in/eNQ-uFvm 📆 We are also attending Benchling’s Benchtalk Europe this week and would love to connect! 🔷 This afternoon we’re hosting a Women in Biotech panel discussion with Benchling, where remarkable biotech women leaders will share first hand advice 🔷 Tomorrow, Ori’s Head of Architecture Matt Todd is speaking on the panel 'Doing better, not just faster, with AI' #manufacturingbrighterfutures #celltherapy #genetherapy #digital #biotechnology

Watch our on-demand webinar on overcoming upstream and downstream process barriers for large-scale AAV production! Watch our esteemed speakers from #EncodedTherapeutics and #ThermoFisherScientific share their valuable insights and strategies to optimize your AAV manufacturing process, ultimately accelerating the development of safe and effective gene therapies. Watch here: https://lnkd.in/gaXj4Vbf Key Takeaways: ✅ Discover an end-to-end solution for the development and commercial production of AAV. ✅ Learn about new products and technologies that can enhance production efficiency, address regulatory concerns, and facilitate the scale-up of AAV production protocols. ✅ Gain a comprehensive understanding of how gene therapy developers are currently tackling critical manufacturing challenges. Stream today to learn more about gene therapy manufacturing!

As transgene size still remains a major limiting factor to unleash the potential of gene therapy, it's great to see a partnership between Roche and SpliceBio forming to explore the use of protein splicing and advance the field. However, manufacturability and safety still remains other bottlenecks within the field of #AAV GTx and will ultimately limit the commercial viability of GTx. That's why at Ascend , we focus all of our AAV manufacturing innovations into balancing yields, quality and potency Reach out to hear about our scalable AAV manufacturing platform or leading suite of analytical tools for in-depth product and process characterization. #genetherapy https://lnkd.in/ePHx9bCs

💡 Join Ian Scanlon as he addresses the challenges in purifying large therapeutic modalities. 🗓️ Date: Thursday, 21st September 2023 ⏰ Time: 12:15 pm - 12:45 pm EST/EDT (GMT-4) 📍 Location: #BPIConf #CGTConf | In Vivo Gene Therapy Manufacturing Track Are you curious about the future of bioprocessing in gene therapy? 🤔 We've got you covered! 🌟 Discover how Next-Generation Nanofiber Technology is changing the game in downstream bioprocessing of viral vectors, extracellular vesicles, and nucleic acid targets. 🧬🔬 🔍 Key highlights: ✅ Unparalleled efficiency in processing fragile macromolecular biologics ✅ Ideal for low titer production and high contaminant scenarios ✅ Innovative solution for purification challenges in novel modalities ✅ Optimized for gene therapy applications #Bioprocessing #NanofiberTechnology #CellTherapy #GeneTherapy #BPIBoston #BecomeTheHEROatBPI

🔬✨ Exploring the world of cell & gene therapy supply chain design Ready to dive into the world of designing high-performance, risk-controlled, and scalable cell & gene supply chains with a digital twin? Following our first two articles on the subject, the latest installment of our series delves into the crucial aspect of determining the optimal manufacturing capacity for CGT! Knowing how many manufacturing units are needed to treat all patients quickly enough is not as simple as it may seem! Running the manufacturing plant at 100% capacity may not always be the best solution. Find out why in this article by Philippe Ducarme and explore some solutions that could benefit you 👉 https://bit.ly/3uZg9yd Stay tuned for the last part of the series that will be coming very soon on our blog. Trust us, you won't want to miss this! 💡💊 #supplychain #digitaltwins #celltherapies #genetherapies #innovation

With 5 gene therapies achieving FDA approval in the last 18 months alone, it has never been more important for developers to optimize and platform their processes to develop scalable, repeatable & cost-effective manufacturing processes to deliver drugs to patients quickly. The inaugural Gene Therapy Process Development Summit is assembling industry leaders in gene therapy to tackle the challenges involved in upscaling transient transfection, optimizing the manufacture of stable cell lines, and establishing clear quality target product profiles to reduce timelines and develop safe and efficacious drugs. Access the full event guide here https://ter.li/qf2qk2 to see the topics being discussed. #genetherapy #processdevelopment #raredisease #GTx #genetherapymanufacturing #rarediseasecmc

Having worked with Cell and Gene therapy companies for the last 4.5 years, I see the immense potential for scalability, but also the need for efficient manufacturing solutions. CAR-T therapy is a hotbed of innovation, and here are 8 companies pioneering allogeneic cell therapy. This "off-the-shelf" approach could revolutionize patient access and I'm interested in speaking with commercial leaders with experience in the Cell and Gene Therapy space to discuss their impact further and what trends you see in this space? #marketinsightsfriday #cellandgene #cart #CAR-T #commercial #pharma #biotech

Podcast: Addressing Barriers in Gene Therapy LISTEN NOW: https://ow.ly/99TO50QGFcf In this sponsored podcast, join us as we delve into addressing regulatory challenges in gene therapy with María Orío, the head of regulatory affairs at Viralgen Vector Core. Uncover the unique challenges faced by the gene therapy industry, from the evolving regulatory landscape to the setting of acceptance criteria with limited available data. In this podcast Viralgen addresses these challenges. Gain valuable insights from the Chemistry, Manufacturing, and Controls perspective, while learning how regulatory agencies are actively supporting sponsors in their quest for life-changing treatments.